Zymeworks (ZYME) to Offer Common Stock and Pre-Funded Warrant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/2/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants
January 21, 2020 4:08 PM ESTVANCOUVER, British Columbia---(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME) (Zymeworks or the Company), a clinicalstage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the Canadian Supplement) to its Canadian short form base shelf prospectus dated November 18, 2019 (the Base Prospectus) in connection with an offering of its common shares and, in lieu of common shares to a certain investor, pre-funded warrants to purchase its common shares (the Offering). The Canadian Supplement was filed with the securities regulatory authorities in each of the provinces and territories of Canada. A preliminary... More
